ResMed (RMD) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of ResMed (NYSE: RMD) in the last few weeks:

• 7/24/2026 – ResMed was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 7/21/2026 – ResMed had its “buy” rating reaffirmed by UBS Group AG. They now have a $300.00 price target on the stock.
• 7/16/2026 – ResMed was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $234.00 price target on the stock.
• 7/15/2026 – ResMed had its price target lowered by Mizuho from $235.00 to $220.00. They now have an “outperform” rating on the stock.
• 7/12/2026 – ResMed had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $235.00 price target on the stock, down from $270.00.
• 7/12/2026 – ResMed was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $235.00 price target on the stock, down from $270.00.
• 7/10/2026 – ResMed had its price target lowered by Jefferies Financial Group Inc. from $240.00 to $225.00. They now have a “hold” rating on the stock.
• 7/8/2026 – ResMed had its price target lowered by Royal Bank Of Canada from $321.00 to $276.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – ResMed had its price target lowered by Wells Fargo & Company from $227.00 to $225.00. They now have an “equal weight” rating on the stock.
• 7/1/2026 – ResMed had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 6/22/2026 – ResMed had its price target lowered by KeyCorp from $290.00 to $266.00. They now have an “overweight” rating on the stock.
• 6/17/2026 – ResMed had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $230.00 price target on the stock, down from $286.00.
• 6/15/2026 – ResMed had its price target lowered by Citigroup Inc. from $340.00 to $270.00. They now have a “buy” rating on the stock.

Insider Activity

In other news, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the completion of the sale, the chief executive officer owned 466,223 shares in the company, valued at $101,893,036.65. This represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 14,973 shares of company stock valued at $3,096,067 over the last quarter. Insiders own 0.65% of the company’s stock.

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.